Wednesday 3 May **(times in PT)**	
09:00-09:15	**Welcome & Opening Address**
09:15-10:00	**Opening Keynote** Antiviral Drug Development for Respiratory Pathogens *Rich Whitley, University of Alabama, Birmingham, AL, USA*
10:00-11:30	**Session 1: Preclinical – Viral Targets** Co-Chairs: TBC
10:00-10:25	Insights from Coronavirus Replication in Developing Antivirals *Mark Denison, Vanderbilt University Medical Center, Nashville, Tennessee, USA*
10:25-10:50	A molecularly engineered lectin for the prevention and treatment of influenza and coronaviruses *David Markovitz, University of Michigan, Ann Arbor, MI, USA*
10:50-11:15	Non-nucleoside RSV polymerase inhibitor *Richard Plemper, Georgia State University, Atlanta, GA, USA*
11:15-11:30	**Panel Discussion**
11:30-11:45	**Coffee Break**

11:45-13:15	**Session 2: Preclinical - Host-Directed Antiviral Therapeutics** Co-Chairs: TBC
11:45-12:10	Harnessing Interferon Responses as Potential Broad Spectrum Respiratory Antiviral Treatments *Vangelis Andreakos, Biomedical Research Foundation, Academy of Athens, Greece*
12:10-12:35	Towards a novel host-targeted anti-infective strategy for COVID-19 and other acute respiratory viral diseases *Stephan Ludwig, Westfaelische-Wilhelms-University, Muenster, Germany*
12:35-13:00	Combined Inhibition of Viral and Host Factors to Maximize Antiviral Activity *Sara Cherry, University of Pennsylvania, Philadelphia PA, USA*
13:00-13:15	**Panel Discussion**
13:15-14:15	**Lunch and Poster Viewing**
14:15-15:45	**Session 3 (Oral Abstract Session 1) - Preclinical Development** Co-Chairs: TBC 6 x 15 min presentations (12 plus 3 for Q&A)
15:45-16.05	**Coffee Break**

16:05-18:00	**Session 4: Clinical Trial Design Issues/Human Challenge/Omics** Co-Chairs: TBC
16:05-16.20	Randomized, Placebo Control Trials including of EUA Drugs *John Beigel, NIAID/NIH, Rockville, MD, USA*
16:20-16.35	RECOVERY Trial *Peter Horby, University of Oxford, Oxford, UK*
16:35-16.50	Human Challenge Model *Chris Chiu, Imperial College, London, UK*
16:50-17.10	Omics in Clinical Trials *Teresa Aydillo, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
17:10-17:25	Fully Remote Trials *Caleb Skipper, University of Minnesota, Minneapolis, MN, USA*
17:25-18.00	**Panel Discussion**

Thursday 4 May (times in PT)	
08:30-10:45	**Session 5: Updates on Clinical Trials** Co-Chairs: TBC
08:30-09:00	**Keynote Talk** REMAP-CAP: Preparing for the Pandemic and Translating the Network into Seasonal Threats *Srinivas Murthy, BC Children's Hospital, Vancouver, Canada*
09:00-09:20	Clinical Trials of Severe Viral Pneumonia *Bin Cao, China-Japan Friendship Hospital, Beijing, China*
09:20-9:40	Monoclonal Antibodies – Current State and Future Directions *James Crowe, Vanderbilt University Medical Center, Nashville, Tennessee, USA*
9:40-10:00	Antiviral Therapies for Children *Janet Englund, Seattle Children's Hospital, Seattle, WA, USA*
10:00-10:20	Small Molecules and Antibodies for RSV *Angela Branche, University of Rochester Medical Center, Rochester, NY, USA*
10:20-10:45	**Panel Discussion**
10:45-11:05	**Coffee Break**
11:05-12:35	**Session 6 (Oral Abstract Session 2) – Antivirals, Monoclonal Antibodies and Combinations** Co-Chairs: TBC 6 x 15 min presentations (12 plus 3 for Q&A)
12:35-13:35	**Lunch and Poster Viewing**

13:35-15:30	**Session 7 - Clinical Trial and Regulatory Issues** Co-Chairs: TBC
13:35-14:05	Keynote Talk: Drug Development, EUAs and The Balance of Preparedness and Data Generation During a Pandemic *Rick Bright, Washington, DC, USA*
14:05-14:25	Regulatory Framework for Moving from EUA to Licensure and Controlled Trials of EUAed agents *Stephanie Troy, US FDA, Silver Spring, MD, USA*
14:25-14:45	Clinical Trial Endpoints for Approval of Antiviral Therapeutics *Marco Cavaleri, EMEA, Amsterdam, The Netherlands*
14:45-15:05	Combination Therapy *Mariana Baz, CHU de Québec-Université Laval, Québec, Canada*
15:05-15:30	The Path Forward for the Treatment of Hospitalized Influenza – Host-Targeted Therapeutics *Kimberley Armstrong, BARDA, Washington D.C., USA*
15:30-15:40	**Panel Discussion**
15:40-16:00	**Coffee Break & Poster viewing**
16:00-18:00	**Session 8 - Treatment Updates** Co-Chairs: TBC
16:00-16:45	State of the Art of COVID-19 Therapy *Cameron Wolfe, Duke University Medical Center, NC, USA*
16:45-18:00	5 x 15 min presentations (12 plus 3 for Q&A)
18:00-19.30	**Poster Reception and Poster viewing**

Friday 5 May **(times in PT)**	
08:30-08:40	**Introduction to Roberts/Tisdale Lectureship** *Maria Zambon, UK Health Security Agency (UKHSA), London, UK / Chair of ISIRV*
08:40-09:25	**Keynote Talk – Roberts/Tisdale Lectureship** Title TBC *Wendy Barclay, Imperial College London, UK*
09:25-10:55	**Session 9: The Right Drug for the Right Patient: Optimizing Antiviral Treatment** Co-Chairs: TBC
09:25-09:50	Role of Genomic Surveillance in Tracking Emergence of Resistance Over Time *Adam Lauring, University of Michigan, Ann Arbor, MI, USA*
09:50-10:15	Developing Diagnostics to Optimize Antiviral Use *Lisa Ng, A* STAR Infectious Diseases Labs, Singapore*
10:15-10:40	Role of Misinformation and Erosion of Social Trust in Response to Pandemics *Rachel Moran, University of Washington, Seattle, WA, USA*
10:40-10:55	**Panel Discussion**
10:55-11:15	**Coffee Break**

11:15-12:45	**Session 10: (Oral Abstract Session 3) – Surveillance & Antiviral Resistance** Co-Chairs: TBC 6 x 15 min presentations (12 plus 3 for Q&A)
12:45-13:45	**Lunch**
13:45-15:15	**Session 11: Access to Care/Global Rollout** Co-Chairs: TBC
13:45-14:10	Global Public Health Security and Justice for Vaccines and Therapeutics in the COVID-19 Pandemic *Sylvie Briand, WHO, Geneva, Switzerland*
14:10-14:35	Enabling Access to Medical Countermeasures by Underserved Populations *Meghan Pennini, HHS, Washington, DC, USA*
14:35-14:50	**Panel Discussion**
14:50- 15.00	**Summary & Close**